Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 23
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
NRX Pharmaceuticals Inc
NRXP
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.40
-0.23
-8.75%
Ult. Agg.: Oct 22, 7:45 PM
$2.44
-0.19
-7.22%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
NRX Pharmaceuticals Financials
NRX Pharmaceuticals (NRXP) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
NRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $0.06 by 833.33 percent. This is a 55.1 percent increase over losses of $(0.98) per share
Benzinga Newsdesk
PRO
NRX Pharmaceuticals Q1 EPS $(0.04) Up From $(0.34) YoY, Sales $1.068M
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.04) per share. This is a 88.24 percent increase over losses of $(0.34) per share from the same period last year. The company reported $1.068 million in
Benzinga Newsdesk
NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
NRx Pharma (NRXP) set to release Q1 earnings on May 18. Analysts expect $19.43 million in revenue, with a loss of 11 cents per share. FDA clearance received for clinical trial.
Avi Kapoor
PRO
NRX Pharmaceuticals Q4 EPS $0.20 Up From $(0.77) YoY, Sales $983.000K
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly earnings of $0.20 per share. This is a 125.97 percent increase over losses of $(0.77) per share from the same period last year. The company reported $983.000 thousand
Benzinga Newsdesk
PRO
As Of September 30, 2025, NRx Pharmaceuticals Had Approximately $7.1M In Cash And Cash Equivalents, Which Is Expected To Support Operations At Least Through Q2 Of 2026
Benzinga Newsdesk
PRO
NRX Pharmaceuticals Q3 EPS $(0.27) May Not Be Comparable To $0.18 Estimate, Sales $242.000K May Not Be Comparable To $15.000M Estimate
Benzinga Newsdesk
